As filed with the Securities and Exchange Commission on February 13, 2026 Registration No. 333-293396 Amendment No. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 HCW BIOLOGICS INC. (Exact name of Registrant as specified in its charter) (State or Other Jurisdiction of Incorporation or Organization) Delaware 2834 82-5024477 Primary Standard Industrial Classification Code Number 2929 N Commerce Parkway Miramar, FL 3 ...

Core Insights - HCW Biologics Inc. presented data on its tetra-valent, second-generation T-Cell Engager (TCE) Program at the SITC 40th Annual Meeting, showcasing advancements in immunotherapy aimed at extending healthspan by addressing inflammation-related diseases [1][2] Company Overview - HCW Biologics is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat diseases associated with chronic inflammation, particularly age-related conditions [4] - The company has developed a new drug discovery technology, the TRBC platform, which allows for the creation of various classes of immunotherapeutic compounds targeting cancer and autoimmune diseases [4] Product Development - The lead T-cell engager product candidate, HCW11-018b, demonstrated significant efficacy in preclinical studies, achieving 100% survival in tumor-bearing mice, while untreated mice showed no survival [2] - The second-generation TCE program is designed to enhance treatment options for a range of solid tumors, including pancreatic cancer and glioblastoma, and may also address autoimmune diseases [2][4] Research Findings - The preclinical evaluation highlighted the unique features of HCW11-018b, including its ability to shrink established tumors in xenograft models and its favorable tolerability profile in non-human primates [2][5] - The tetra-valent construct is designed to overcome immunosuppressive tumor microenvironments and activate exhausted T cells, showing long serum half-life and favorable pharmacokinetics [5] Future Directions - The company is conducting ongoing preclinical evaluation studies for selected molecules based on promising data and has established licensing programs for some proprietary molecules [6]

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential trading opportunities before the market opens [1] Premarket Gainers - Vestand Inc. (VSTD) is up 96% at $2.53 - GlucoTrack, Inc. (GCTK) is up 86% at $9.09 - HCW Biologics Inc. (HCWB) is up 71% at $5.68 - Millennium Group International Holdings Limited (MGIH) is up 31% at $2.87 - IBEX Limited (IBEX) is up 27% at $38.74 - BGSF, Inc. (BGSF) is up 27% at $8.19 - Apimeds Pharmaceuticals US, Inc (APUS) is up 23% at $2.40 - Asset Entities Inc. (ASST) is up 16% at $10.39 - HUB Cyber Security Ltd. (HUBC) is up 10% at $2.71 - BioNexus Gene Lab Corp. (BGLC) is up 9% at $4.70 [3] Premarket Losers - Rent the Runway, Inc. (RENT) is down 21% at $6.17 - XTI Aerospace, Inc. (XTIA) is down 19% at $1.64 - RH (RH) is down 9% at $206.00 - Frequency Electronics, Inc. (FEIM) is down 9% at $30.96 - Global Mofy AI Limited (GMM) is down 9% at $1.99 - Jeffs' Brands Ltd (JFBR) is down 8% at $4.33 - Kindly MD, Inc. (NAKA) is down 8% at $3.60 - Empro Group Inc. (EMPG) is down 7% at $12.38 - Rezolve AI PLC (RZLV) is down 6% at $6.32 - NLS Pharmaceutics AG (NLSP) is down 5% at $2.03 [4]

Shares of Adobe Inc. ADBE rose sharply in pre-market trading after the company posted better-than-expected third-quarter results and raised its fiscal 2025 outlook after Thursday's closing bell.Adobe reported quarterly earnings of $5.31 per share, which beat the analyst estimate of $5.18. Quarterly revenue came in at $5.99 billion, which beat the Street estimate of $5.91 billion, according to data from Benzinga Pro.Adobe shares jumped 4.4% to $365.80 in the pre-market trading session.Here are some other sto ...

Core Viewpoint - HCW Biologics (HCWB.US) experienced a nearly 70% surge in stock price, reaching $5.81, following the announcement of a second-generation immunotherapy drug based on Pembrolizumab targeting solid tumors, particularly pancreatic and ovarian cancers [1] Company Summary - HCW Biologics has developed a novel proprietary TRBC product discovery and development platform technology for its new immunotherapy drug [1] - The company highlighted that immune checkpoint inhibitors (ICIs), introduced in cancer treatment since 2011, are considered groundbreaking therapies but have shown a lack of immune cell co-stimulation activity, which diminishes their anti-tumor efficacy [1]

Group 1 - HCW Biologics experienced a nearly 70% surge in stock price, reaching $5.81, following the announcement of a second-generation immunotherapy drug based on Pembrolizumab targeting solid tumors, particularly pancreatic and ovarian cancers [1] - The company utilizes a novel proprietary TRBC product discovery and development platform technology for its new drug [1] - Since the introduction of immune checkpoint inhibitors (ICIs) in cancer treatment in 2011, they have been recognized as breakthrough therapies, although the company noted that preclinical and clinical studies indicate ICIs lack co-stimulatory activity of immune cells, reducing their anti-tumor efficacy [1]

Core Viewpoint - HCW Biologics (HCWB.US) experienced a nearly 70% surge in stock price, reaching $5.81, following the announcement of a second-generation immunotherapy drug based on pembrolizumab targeting solid tumors, particularly pancreatic and ovarian cancers [1] Company Summary - The company has developed a novel proprietary TRBC product discovery and development platform technology for its new immunotherapy drug [1] - Since the introduction of immune checkpoint inhibitors (ICIs) in cancer treatment in 2011, they have been recognized as breakthrough therapies [1] - The company highlighted that preclinical and clinical studies indicate that ICIs lack co-stimulatory activity of immune cells, which diminishes their anti-tumor efficacy [1]

Core Points - HCW Biologics Inc. announced a 1-for-40 reverse stock split effective April 11, 2025, to comply with Nasdaq's minimum bid price requirement of $1.00 per share [1][2] - The reverse stock split will reduce the number of shares outstanding from approximately 44,934,120 to about 1,123,353, while the total authorized shares will remain at 250,000,000 [3] - The reverse stock split will not affect stockholders' percentage ownership, except for those who would receive fractional shares, who will instead receive one whole share [2][3] Company Overview - HCW Biologics is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies aimed at extending health span by addressing inflammation linked to age-related diseases [6] - The company utilizes two drug discovery platforms: the TOBI™ platform, which has produced several molecules including HCW9218 and HCW9302, and the TRBC platform, which employs a unique protein-based backbone for immunotherapeutics [6]